ArticleApplied clinical informatics2025
A Measurement Science Framework to Optimize CDS for Opioid Use Disorder Treatment in the ED.
Article in Applied clinical informatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
In the emergency department-initiated buprenorphine for opioid use disorder (EMBED) trial, a clinical decision support (CDS) tool had no effect on rates of buprenorphine initiation in emergency department (ED) patients with opioid use disorder. The Agency for Healthcare Research and Quality (AHRQ) recently released a CDS Performance Measure Inventory to guide data-driven CDS development and evaluation. Through partner co-design, we tailored AHRQ inventory measures to evaluate EMBED CDS performance and drive improvements.Relevant AHRQ inventory measures were selected and adapted using a partner co-design approach grounded in consensus methodology, with three iterative, multidisciplinary partner working group sessions involving stakeholders from various roles and institutions; meetings were followed by postmeeting surveys. The co-design process was divided into conceptualization, specification, and evaluation phases building on the Centers for Medicare and Medicaid Services' measure life cycle framework. Final measures were evaluated in three EDs in a single health system from January 1, 2023, to December 31, 2024.The partner working group included 25 members. During conceptualization, 13 initial candidate metrics were narrowed to 6 priority categories. These were further specified and validated as the following measures, presented with preliminary values based on the use of the current (i.e., preoptimization) EMBED CDS: eligible encounters with CDS engagement, 5.0% (95% confidence interval: 4.3-5.8%); teamwork on ED initiation of buprenorphine, 39.9% (32.5-47.3%); proportion of eligible users who used EMBED, 58.3% (50.9-65.8%); time spent on EMBED, 29.0 seconds (20.4-37.7 seconds); proportion of buprenorphine orders placed through EMBED, 6.5% (3.4-9.6%); and task completion, 13.8% (8.9-18.7%) for buprenorphine order/prescription.A measurement science framework informed by partner co-design was a feasible approach to develop measures to guide CDS improvement. Subsequent research could adapt this approach to evaluate other CDS applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.